Blanket Purchase Agreement 36F79725D0093-36C24626A0027
Award Date 8/20/26
Last Date to Order 8/19/27
Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed Similar IDVs
- Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs (VA), Veterans Integrated Service Network 10, for the supply of PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent. The contract, valued at $5.413 million with a ceiling date of September 30, 2030, is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is not set-aside....
- Veterans Integrated Service Network 8 (VISN 8), on behalf of the Department of Veterans Affairs, established a single-award Blanket Purchase Agreement with Progenics Pharmaceuticals Inc. on August 1, 2024, with a ceiling of $2,634,365.60 and a completion date of September 30, 2028, against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA procures PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic imaging agent used in positron emission tomography scans...
- Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., has been awarded a single-award Blanket Purchase Agreement by Veterans Integrated Service Network 15 (VISN 15) for the supply of PYLARIFY (piflufolastat F-18) injection, a diagnostic radiopharmaceutical used in positional emission tomography (PET) imaging for prostate cancer detection and localization. The BPA has a ceiling value of $793,918.40 and runs through October 31, 2027, with performance occurring in North...
- This Blanket Purchase Agreement, awarded January 6, 2026, to Progenics Pharmaceuticals Inc. (operating as a division of Lantheus Medical Imaging, Inc.) by Veterans Integrated Service Network 17, establishes a single-award indefinite delivery vehicle for the procurement of PYLARIFY (piflufolastat F-18), a diagnostic radiopharmaceutical imaging agent. The contract, valued at $9,071,800 and extending through January 4, 2031, operates under the Pharmaceuticals and Drugs Federal Supply Schedule...
- Veterans Integrated Service Network 21 established a Blanket Purchase Agreement with Progenics Pharmaceuticals Inc. on January 15, 2023, against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), for radioactive diagnostic agents indicated for positron emission tomography imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer, with a $5.5 million ceiling and a total small business set-aside designation. The BPA covers performance at the...
- Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., was awarded a single-award Blanket Purchase Agreement by Veterans Integrated Service Network 8 (VISN 8) of the Department of Veterans Affairs effective April 1, 2023, with a ceiling value of $5.73 million and ultimate completion date of December 31, 2026. The contract procures PYLARIFY Injection (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET) scans for the...
- Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., was awarded a single-award Blanket Purchase Agreement by Veterans Integrated Service Network 9 (VISN 9) on November 1, 2022, with a ceiling value of $4.3 million and a performance period extending through October 31, 2027. This Blanket Purchase Agreement, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with no set-aside designation, provides the primary contract vehicle for the...
- GSA issued the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract to Progenics Pharmaceuticals Inc. on April 1, 2025, with a ceiling value of $592.78 million and a performance period through March 31, 2030. Progenics, a division of Lantheus Medical Imaging, Inc., is a for-profit pharmaceutical company with no set-aside designation on the parent schedule. The contractor supplies PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent used in positron...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Blanket Purchase Agreement to Progenics Pharmaceuticals Inc. for PYLARIFY products and services. The single award BPA, valued at over $1.3 million, was issued on July 15, 2022 against the Pharmaceuticals and Drugs Federal Supply Schedule master contract for the period of July 15, 2022 through June 14, 2024. Performance will take place in New York, New York. The BPA calls authorize...
- The key products and services being delivered under this Blanket Purchase Agreement (BPA) federal contract Indefinite Delivery Vehicle (IDV) are PYLARIFY (piflufolastat F-18), a radiopharmaceutical drug used for positron emission tomography (PET) imaging of prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract, valued at up to $1,188,615.44, was awarded by the U.S....
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
BPA Call 36C24626A0027-36C24626N0890 | Progenics Pharmaceuticals Inc. | $4.5m | 8/20/26 | 8/19/27 | 8/4/26 |